Program
Anti-PD-1/IL-2 Fusion Protein TEV-56278
Also written as “TEV-56278”, “Intervention1:FXB0871” and “Intervention2:FXB0871”.
In Fosun Pharma’s pipeline, PD-1/IL-2
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharmaits history only | 11 open or running | phase 1since Apr 7, 2026 | Apr 7, 2026 | Apr 23, 2030phase 1 · NCT07558200 |
| Teva Pharmaceutical Industriesits history only | 11 open or running | phase 1since Jun 10, 2024 | Jun 10, 2024 | May 26, 2029phase 1 · NCT06480552 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 10, 2024First study: phase 1 study in Advanced Solid TumorsNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT06480552 · 240 planned · United States, Canada
- Apr 7, 2026Fosun Pharma’s first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Fosun PharmaFosun Pharma · NCT07558200 · 138 planned · China
Ahead
- May 26, 2029Primary completion: phase 1 study in Advanced Solid TumorsTeva Pharmaceutical Industries · NCT06480552
- Apr 23, 2030Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungFosun Pharma · NCT07558200
TargetBeta
“PD-1/IL-2”the company's pipeline, read by Claude · source
“A recombinant fusion protein composed of an antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Daxokafusp Alfa | Sanofi | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07558200Carcinoma, Non-Small-Cell Lung · China | 1 | Not yet recruiting | Fosun Pharma | Apr 23, 2030 | 138 |
| NCT06480552Advanced Solid Tumors · United States, Canada | 1 | Recruiting | Teva Pharmaceutical Industries | May 26, 2029 | 240 |
How it is read
Names in the registry
- “TEV-56278”, 1 entry
- “Intervention1:FXB0871”, 1 entry
- “Intervention2:FXB0871”, 1 entry
- “Intervention3:FXB0871”, 1 entry
- “Intervention4:FXB0871”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.